We founded CeleCor Therapeutics to improve the treatment of ST-segment elevation myocardial infarctions (STEMI heart attacks) at the first point of medical contact. Each year, 800,000 people in the United States have an acute myocardial infarction (AMI), or heart attack, a life-threatening condition in which blood flow to the heart muscle is suddenly decreased or blocked by a blood clot in one or more of the coronary vessels. To significantly reduce deaths, we are developing a prompt, potent and predicatable therapy that restores blood flow rapidly and can be subcuatneously administered in the critical time before a patient reaches the hospital.